879488-19-4

Usage

Uses

Used in Organic Synthesis:
2-(4-Iodo-1H-pyrazol-1-yl)-N,N-diMethylethanaMine is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows for versatile chemical reactions, facilitating the synthesis of a broad range of molecules with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(4-Iodo-1H-pyrazol-1-yl)-N,N-diMethylethanaMine is employed as a key component in the development of new drugs and therapeutic agents. Its potential biological activity makes it a promising candidate for the treatment of various diseases and medical conditions.
Used in Drug Development:
2-(4-Iodo-1H-pyrazol-1-yl)-N,N-diMethylethanaMine is utilized as a starting material in the design and synthesis of novel drug candidates. Its unique chemical properties enable the creation of innovative molecules with improved pharmacological profiles, potentially leading to the discovery of more effective treatments for various health issues.
Used in Chemical Research:
In the field of chemical research, 2-(4-Iodo-1H-pyrazol-1-yl)-N,N-diMethylethanaMine is used as a model compound to study various chemical reactions and mechanisms. Its reactivity and structural features provide valuable insights into the behavior of similar compounds, contributing to the advancement of chemical knowledge and understanding.
Used in Material Science:
2-(4-Iodo-1H-pyrazol-1-yl)-N,N-diMethylethanaMine may also find applications in material science, where its unique properties can be harnessed to develop new materials with specific characteristics. Its potential use in the creation of advanced materials for various industries, such as electronics, energy, and environmental applications, is currently being explored.

Upstream product

• 506-59-2 N,N-dimethylammonium chloride 
• 879487-88-4 4-iodo-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 
• 1408334-75-7 2-(4-iodo-1H-pyrazol-1-yl)ethanol 
• 1578246-28-2 2-(4-iodo-1H-pyrazol-1-yl)ethyl 4-methylbenzenesulfonate 
• 124-40-3 dimethyl amine 
• 3469-69-0 4-iodopyrazole 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 

Downstream Products

• 1578246-31-7 4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-2-methoxyaniline 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

INHIBITOR COMPOUNDS

The present invention relates to compounds of formula (I), wherein R, R, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 - also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R1 to R5, A, B, Z, Z1 and Z2 are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

SUBSTITUTED BIPHENYL DERIVATIVE

The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R3 represents a C1-C6 alkyl group, and so on; and R4 represents a C1-C6 alkyl group, and so on.